On December 8, 2020 TAE Life Sciences (TLS) reported a new joint venture (JV) agreement with Neuboron Medtech (Neuboron) for the widespread adoption of Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) for the treatment of invasive, recurrent and difficult to treat cancers (Press release, TAE Life Sciences, DEC 8, 2020, View Source [SID1234572716]). Under the agreement, TLS becomes the second shareholder in Neuboron Therapy System (NTS), originally a wholly owned subsidiary of Neuboron.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each day, 50,000 people are diagnosed with cancer worldwide, and the ability to provide a unique approach to deliver targeted therapy with biological precision is critical. This agreement is expected to further expand NTS’s influence and speed up the deployment of Neuboron’s AB-BNCT system.

Established in 2017, NTS has obtained Neuboron’s IP and technology licenses in the field of AB-BNCT. Through TLS’s new capital contribution, NTS becomes an equity joint venture with international capital. The business scope of NTS covers research, development, manufacturing, system integration, clinical trials, market accesses and sales of AB-BNCT system.

AB-BNCT is a powerful alternative cancer treatment to traditional radiotherapy and other particle therapies because it delivers targeted radiation selectively to cancer cells and spares surrounding healthy tissue. BNCT has demonstrated compelling responses for some of the most difficult to treat cancers and has been successful in treating cancer patients for whom other treatment options have been exhausted. Typically, patients only need to undergo 1 or 2 treatments with BNCT vs. dozens with conventional therapies. This provides patients with greater flexibility in their treatment regimen as well as enhance efficiency of the cancer center.

"China is one of the largest market opportunities for BNCT. Our partnership with Neuboron Therapy System includes delivering our accelerator-based neutron system and has the potential to transform the cancer therapy landscape. BNCT provides a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers like gliomas, head and neck tumors, and melanomas," said Bruce Bauer, Chief Executive Officer of TAE Life Sciences. "We have found a true partner in NTS as we both work toward the common goal to enable AB-BNCT to become a first-line treatment for patients globally."

On December 8, 2020 Curis, Inc. presented the corporate presentation (Presentation, Curis, DEC 8, 2020, View Source [SID1234572403]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 8, 2020 PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) reported that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company’s common stock from the Nasdaq Global Select Market ("Nasdaq") (Press release, PDL BioPharma, DEC 8, 2020, View Source [SID1234572439]). PDL expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its common stock on or about December 28, 2020 and to suspend trading of its common stock on the Nasdaq Global Select Market prior to the opening of trading on December 31, 2020. PDL does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. PDL intends to file a certificate of dissolution with the Delaware Secretary of State on or about January 4, 2021 and close its stock transfer books at the close of business on this date. The official delisting of PDL’s common stock will be effective on or about January 7, 2021 – 10 days after the filing of the Form 25.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PDL also intends to file a Form 15 with the SEC as soon as practicable following the effectiveness of the delisting to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934, as amended. The suspension of PDL’s reporting obligations, including the obligation to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, will be effective upon filing the Form 15. PDL does however intend to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 in March 2021.

The voluntary delisting and deregistration are part of PDL’s previously announced voluntary Plan of Dissolution that was approved by the Board of Directors in February 2020 and at the Annual Meeting of the Company’s stockholders on August 19, 2020. The Company’s Board of Directors considered a number of factors in determining to delist and deregister PDL’s common stock, including the costs and expenses associated with being a publicly traded company, the auditing, legal and other costs associated with continuing to make SEC filings, and the burdens placed on Company management to comply with the continued listing and reporting requirements, all in light of the Company’s planned dissolution and liquidation.

On December 8, 2020 RayzeBio, Inc., which launched this year to develop a broad pipeline of targeted radiopharmaceuticals against validated solid tumor targets, reported a $105 million Series B financing led by Venrock Healthcare Capital Partners (VHCP) alongside new investors OrbiMed, Redmile Group, Viking Global Investors, Logos Capital, Cormorant Asset Management, LifeSci Venture Partners, Alexandria Venture Investments and others (Press release, RayzeBio, DEC 8, 2020, View Source [SID1234572455]). Also participating were existing investors from RayzeBio’s $45 million Series A financing, including venBio Partners, Versant Ventures and Samsara BioCapital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the past several months, we’ve built an exciting pipeline of seven programs, expanded our leadership team, and secured several key business partnerships," said Ken Song, M.D., president and CEO of RayzeBio. "I am appreciative of the enthusiastic support from our elite group of investors. This additional capital allows us to fully invest in the potential of radiopharmaceuticals as a transformative therapy for cancer patients."

With $150 million of capital from the two financings, RayzeBio will advance multiple programs in parallel toward the clinic. The company also is expanding its headquarters in San Diego with plans to further internalize key research and development capabilities.

"We’ve been following the radiopharmaceuticals space for several years and are impressed by the approach RayzeBio is taking to build a broad pipeline," said Bong Koh, M.D., lead investor from VHCP who is joining the RayzeBio Board of Directors in connection with the Series B.

In addition to the financing, RayzeBio also announced the appointment of Gary Li, Ph.D. as senior vice president and head of biology and translational medicine and Eric Bischoff as senior vice president of development and operations. Dr. Li is an accomplished cancer cell biologist with over 15 years of drug development experience, with leadership positions at Ignyta and QED Therapeutics prior to joining RayzeBio. Mr. Bischoff has had an extensive and diverse career in drug discovery and development for more than 20 years including key roles at two oncology companies, Aragon and Seragon, which were both acquired.

On December 8, 2020 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage company focused on making a positive impact on patients’ lives, reported that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13th Annual LD Micro Main Event Conference on Monday, December 14th at 10:40 a.m. ET (Press release, PLUS THERAPEUTICS, DEC 8, 2020, View Source [SID1234572404]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For conference participants, a live webcast of the presentation can be found by visiting the home page of the event at View Source A subsequent archived recording of the Company’s presentation will be available under the ‘Events’ tab of the Investor Relations section of the Plus Therapeutics website at www.plustherapeutics.com.